Market Overview

Tilray® 2:100 Product Shows Promise in Canada's First Pediatric Study of Mixed THC/CBD Medical Cannabis Oil for Children with Drug-Resistant Epilepsy

Share:

Research conducted at The Hospital for Sick Children (SickKids)
establishes promising safety and tolerability data for Tilray 2:100 oil
for children with drug-resistant epilepsy (DRE) due to Dravet Syndrome

Tilray Inc. (NASDAQ:TLRY), a global pioneer in medical cannabis
production and distribution, is pleased to announce that a study
featuring Tilray 2:100, a medical cannabis oil containing high amounts
of cannabidiol (CBD) and conservative amounts of tetrahydrocannabinol
(THC), has shown promising results for children with drug-resistant
epilepsy (DRE) due to Dravet Syndrome. The findings of the Phase II
trial, which was designed and conducted by researchers at The Hospital
for Sick Children in Toronto (SickKids), were published
today
in the peer-reviewed medical journal Annals of Clinical and
Translational Neurology.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180801005510/en/

(Photo: Business Wire)

(Photo: Business Wire)

"We are excited by the encouraging results of this study and the ability
to already offer this highly concentrated CBD product to patients in
Canada. We developed this product based on a strong existing evidence
base that a combination cannabinoid product may have numerous benefits
in this difficult to treat patient population," said Catherine Jacobson,
Director of Tilray's Clinical Research Program. "In the participants who
reached the target treatment dose there was a statistically significant
reduction in motor seizures, and an increase in seizure-free days
compared to those who did not reach the target dose. Promising
clinically beneficial effects were observed, including a reduction in
seizure frequency and improvements in certain aspects of adaptive
functioning and quality of life measures."

"This is an important study, providing valuable data about the safety
and efficacy of a high CBD and low THC medication to treat Dravet
syndrome, a disorder with high morbidity and mortality," said Orrin
Devinsky, MD, Chair of Tilray's Medical Advisory Board and Director of
the Comprehensive Epilepsy Center at New York University Langone Medical
Center.

Tilray 2:100 contains the highest concentration of cannabis-extracted
CBD in a medical cannabis product available through Canada's Access to
Cannabis for Medical Purposes Regulations (ACMPR). Tilray 2:100 has a
target concentration of 100mg/ml CBD and 2mg/ml THC for a total
cannabinoid amount of 4,000mg CBD and 80mg THC in each 40ml bottle.

Tilray 2:100 is available to pediatric patients through the ACMPR. As
supply increases, the product will be made available to other patients
in need. To help support access to this product, Tilray is proud to
offer a discounted introductory price, as well as a compassionate
pricing program based on financial need. For information on Tilray 2:100
and the compassionate pricing program, please call Tilray's Patient
Services team at 1-844-TILRAY1.

As the first study of its kind to examine with rigor the dosing and
tolerability of a mixed cannabinoid product containing both CBD and THC
in children with DRE due to Dravet Syndrome, these results set the
foundation for further work to advance successful treatment and outcomes
for this population of children who until now, had little hope for
better health outcomes.

A limitation in this study concerns the small number of participants,
the majority of whom were already taking a prescribed antiepileptic
drug. Tilray donated product for the trial and funded the research. Next
steps include additional research with more participants and variable
doses of combined THC/CBD.

About Tilray®

Tilray is
a global pioneer in the research, cultivation, production and
distribution of medical cannabis and cannabinoids currently serving tens
of thousands of patients in ten countries spanning five continents.

View Comments and Join the Discussion!